Oscar Tahuahua, Medical Oncology Fellow at National Cancer Institute (Mexico), shared an article by Nicola Normanno et al. on X:
“ctDNA in NSCLC provides a powerful tool for MRD detection, relapse stratification, and treatment monitoring. Its utility is established, but clinical integration depends on standardized assays, sensitivity, and validation.”
Circulating tumour DNA in early-stage and locally advanced NSCLC: ready for clinical implementation?
Authors: Nicola Normanno, Alessandro Morabito, Anna Maria Rachiglio, Vincenzo Sforza, Lorenza Landi, Emilio Bria, Angelo Delmonte, Federico Cappuzzo & Antonella De Luca
